Vitamin A: A drug for prevention of restenosis/reocclusion after percutaneous coronary intervention?

Clinical Science

Volumn 114, Issue 1-2, 2008, Pages 19-25

  Gidlöf, Andreas C ^a   Ocaya, Pauline ^b   Krivospitskaya, Olesya ^b   Sirsjö, Allan ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ÖREBRO UNIVERSITY   (Sweden)

Author keywords

Atherosclerosis; Intimal hyperplasia; Percutaneous vascular intervention; Restenosis; Retinoid; Vascular injury; Vitamin A

Indexed keywords

RETINOL;

ARTERY INTIMA PROLIFERATION; BLOOD CLOTTING; BLOOD VESSEL INJURY; CELL DIFFERENTIATION; CELL MIGRATION; DRUG EFFECT; FIBRINOLYSIS; HUMAN; NEOPLASM; NONHUMAN; PATHOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PSORIASIS; RESTENOSIS; REVIEW; SMOOTH MUSCLE FIBER; ANIMAL; CORONARY ARTERY DISEASE; DISEASE MODEL; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR SMOOTH MUSCLE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DISEASE MODELS, ANIMAL; HUMANS; MUSCLE, SMOOTH, VASCULAR; VITAMIN A;

EID: 38349018249     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20070090     Document Type: Review

References (85)

1. Hansson, G. K. (2005) Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685-1695
2. Kadakia, R. A. and Ferguson, J. J. (2005) Optimal antithrombotic treatment for percutaneous coronary intervention. Minerva Cardioangiol. 53, 15-42
3. Schwartz, R. S. and Henry, T. D. (2002) Pathophysiology of coronary artery restenosis. Rev. Cardiovasc. Med. 3 (Suppl. 5), S4-S9
4. Mitra, A. K. and Agrawal, D. K. (2006) In stent restenosis: bane of the stent era. J. Clin. Pathol. 59, 232-239
5. Butany, J., Carmichael, K., Leong, S. W. and Collins, M. J. (2005) Coronary artery stents: identification and evaluation. J. Clin. Pathol. 58, 795-804
6. Hoffmann, R., Mintz, G. S., Dussaillant, G. R. et al. (1996) Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 94, 1247-1254
7. Farb, A., Sangiorgi, G., Carter, A. J. et al. (1999) Pathology of acute and chronic coronary stenting in humans. Circulation 99, 44-52
8. Farb, A., Weber, D. K., Kolodgie, F. D., Burke, A. P. and Virmani, R. (2002) Morphological predictors of restenosis after coronary stenting in humans. Circulation 105, 2974-2980
9. Lefkovits, J. and Topol, E. J. (1997) Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention. Prog. Cardiovasc. Dis. 40, 141-158
10. Eisenberg, M. J. and Konnyu, K. J. (2006) Review of randomized clinical trials of drug-eluting stents for the prevention of in-stent restenosis. Am. J. Cardiol. 98, 375-382
11. Sousa, J. E., Costa, M. A., Abizaid, A. et al. (2001) Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 103, 192-195
12. Sousa, J. E., Costa, M. A., Abizaid, A. C. et al. (2001) Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 104, 2007-2011
13. Granada, J. F., Kaluza, G. L. and Raizner, A. (2003) Drug-eluting stents for cardiovascular disorders. Curr. Atheroscler. Rep. 5, 308-316
14. Menown, I., Lowe, R. and Penn, I. (2005) Passive stent coatings in the drug-eluting era. J. Invasive Cardiol. 17, 222-228
15. Joner, M., Finn, A. V., Farb, A. et al. (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 48, 193-202
16. Curfman, G. D., Morrissey, S., Jarcho, J. A. and Drazen, J. M. (2007) Drug-eluting coronary stents: promise and uncertainty. N. Engl. J. Med. 356, 1059-1060
17. Maisel, W. H. (2007) Unanswered questions: drug-eluting stents and the risk of late thrombosis. N. Engl. J. Med. 356, 981-984
18. Virmani, R., Farb, A., Guagliumi, G. and Kolodgie, F. D. (2004) Drug-eluting stents: caution and concerns for long-term outcome. Coron. Artery Dis. 15, 313-318
19. Streb, J. W. and Miano, J. M. (2003) Retinoids: pleiotropic agents of therapy for vascular diseases? Curr. Drug Targets Cardiovasc. Haematol. Disord. 3, 31-57
20. Barstad, R. M., Hamers, M. J., Stephens, R. W. and Sakariassen, K. S. (1995) Retinole acid reduces induction of monocyte tissue factor and tissue factor/factor VIIa-dependent arterial thrombus formation. Blood 86, 212-218
21. Bastien, J. and Rochette-Egly, C. (2004) Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene 328, 1-16
22. Balmer, J. E. and Blomhoff, R. (2002) Gene expression regulation by retinoic acid. J. Lipid Res. 43, 1773-1808
23. Napoli, J. L. (1999) Retinoic acid: its biosynthesis and metabolism. Prog. Nucleic Acid Res. Mol. Biol. 63, 139-188
24. Ross, A. C. (2003) Retinoid production and catabolism: role of diet in regulating retinol esterification and retinoic acid oxidation. J. Nutr. 133, 291S-296S
25. Miano, J. M., Kelly, L. A., Artacho, C. A., Nuckolls, T. A., Piantedosi, R. and Blaner, W. S. (1998) All-trans-retinoic acid reduces neointimal formation and promotes favorable geometric remodeling of the rat carotid artery after balloon withdrawal injury. Circulation 98, 1219-1227
26. Neuville, P., Yan, Z., Gidlöf, A. et al. (1999) Retinoic acid regulates arterial smooth muscle cell proliferation and phenotypic features in vivo and in vitro through an RARα-dependent signaling pathway. Arterioscler. Thromb. Vasc. Biol. 19, 1430-1436
27. Lee, C. W., Park, S. J., Park, S. W., Kim, J. J., Hong, M. K. and Song, J. K. (2000) All-trans-retinoic acid attenuates ncointima formation with acceleration of reendothelialization in balloon-injured rat aorta. J. Korean Med. Sci. 15, 31-36
28. Wiegman, P. J., Barry, W. L., McPherson, J. A. et al. (2000) All-trans-retinoic acid limits restenosis after balloon angioplasty in the focally atherosclerotic rabbit: a favorable effect on vessel remodeling. Arterioscler. Thromb. Vasc. Biol. 20, 89-95
29. Chen, J., He, B., Zheng, D., Zhang, S., Liu, J. and Zhu, S. (1999) All-trans retinoic acid reduces intimal thickening after balloon angioplasty in atherosclerotic rabbits. Chin. Med. J. 112, 121-123
30. Herdeg, C., Oberhoff, M., Baumbach, A. et al. (2003) Effects of local all-trans-retinoic acid delivery on experimental atherosclerosis in the rabbit carotid artery. Cardiovasc. Res. 57, 544-553
31. Axel, D. I., Frigge, A., Dittmann, J. et al. (2001) All-trans retinoic acid regulates proliferation, migration, differentiation, and extracellular matrix turnover of human arterial smooth muscle cells. Cardiovasc. Res. 49, 851-862
32. Farzaneh-Far, A., Weissberg, P. L., Proudfoot, D. and Shanahan, C. M. (2001) Transcriptional regulation of matrix gla protein. Z. Kardiol. 90 (Suppl. 3), 38-42
33. Hayashi, A., Suzuki, T. and Tajima, S. (1995) Modulations of elastin expression and cell proliferation by retinoids in cultured vascular smooth muscle cells. J. Biochem. (Tokyo) 117, 132-136
34. Leville, C. D., Dassow, M. S., Seabrook, G. R., Jean-Claude, J. M., Towne, J. B. and Cambria, R. A. (2000) All-trans-retinoic acid decreases vein graft intimal hyperplasia and matrix metalloproteinase activity in vivo. J. Surg. Res. 90, 183-190
35. Kato, S., Sasaguri, Y. and Morimatsu, M. (1993) Down-regulation in the production of matrix metalloproteinase 1 by human aortic intimal smooth muscle cells. Biochem. Mol. Biol. Int. 31, 239-248
36. James, T. W., Wagner, R., White, L. A., Zwolak, R. M. and Brinckerhoff, C. E. (1993) Induction of collagenase and stromelysin gene expression by mechanical injury in a vascular smooth muscle-derived cell line. J. Cell. Physiol. 157, 426-437
37. Vassalli, J. D., Sappino, A. P. and Belin, D. (1991) The plasminogen activator/plasmin system. J. Clin. Invest. 88, 1067-1072
38. Bochaton-Piallat, M. L., Gabbiani, G. and Pepper, M. S. (1998) Plasminogen activator expression in rat arterial smooth muscle cells depends on their phenotype and is modulated by cytokines. Circ. Res. 82, 1086-1093
39. Bulens, F., Ibanez-Tallon, I., Van Acker, P. et al. (1995) Retinoic acid induction of human tissue-type plasminogen activator gene expression via a direct repeat element (DR5) located at -7 kilobases. J. Biol. Chem. 270, 7167-7175
40. Watanabe, A., Kanai, H., Arai, M. et al. (2002) Retinoids induce the PAI-1 gene expression through tyrosine kinase-dependent pathways in vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 39, 503-512
41. Gotwals, P. J., Chi-Rosso, G., Lindner, V. et al. (1996) The α1β1 integrin is expressed during neointima formation in rat arteries and mediates collagen matrix reorganization. J. Clin. Invest. 97, 2469-2477
42. 1- integrin in vascular smooth muscle cells and alters adhesion to fibronectin. Am. J. Physiol. Heart Circ. Physiol. 279, H382-H387
43. Johst, U., Betsch, A., Wiskirchen, J. et al. (2003) All-trans and 9-cis retinoid acids inhibit proliferation, migration, and synthesis of extracellular matrix of human vascular smooth muscle cells by inducing differentiation in vitro. J. Cardiovasc. Pharmacol. 41, 526-535
44. Anderson, R. J., Ray, C. J. and Hattler, B. G. (1998) Retinoic acid regulation of renal tubular epithelial and vascular smooth muscle cell function. J. Am. Soc. Nephrol. 9, 773-781
45. Peclo, M. M. and Printseva, O. (1987) Retinoic acid enhances the proliferation of smooth muscle cells. Experientia 43, 196-198
46. Hagiwara, H., Inoue, A., Nakajo, S., Nakaya, K., Kojima, S. and Hirose, S. (1996) Inhibition of proliferation of chondrocytes by specific receptors in response to retinoids. Biochem. Biophys. Res. Commun. 222, 220-224
47. Miano, J. M., Topouzis, S., Majesky, M. W. and Olson, E. N. (1996) Retinoid receptor expression and all-trans retinoic acid-mediated growth inhibition in vascular smooth muscle cells. Circulation 93, 1886-1895
48. Wakino, S., Kintscher, U., Kim, S. et al. (2001) Retinoids inhibit proliferation of human coronary smooth muscle cells by modulating cell cycle regulators. Arterioscler. Thromb. Vasc. Biol. 21, 746-751
49. Chen, S. and Gardner, D. G. (1998) Retinoic acid uses divergent mechanisms to activate or suppress mitogenesis in rat aortic smooth muscle cells. J. Clin. Invest. 102, 653-662
50. Haxsen, V., Adam-Stitah, S., Ritz, E. and Wagner, J. (2001) Retinoids inhibit the actions of angiotensin II on vascular smooth muscle cells. Circ. Res. 88, 637-644
51. Pakala, R. and Benedict, C. R. (2000) RARγ agonists inhibit proliferation of vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 35, 302-308
52. Kosaka, C., Sasaguri, T., Komiyama, Y. and Takahashi, H. (2001) All-trans retinoic acid inhibits vascular smooth muscle cell proliferation targeting multiple genes for cyclins and cyclin-dependent kinases. Hypertens. Res. 24, 579-588
53. Watanabe, N., Kurabayashi, M., Shimomura, Y. et al. (1999) BTEB2, a Kruppel-like transcription factor, regulates expression of the SMemb/Nonmuscle myosin heavy chain B (SMemb/NMHC-B) gene. Circ. Res. 85, 182-191
54. Shindo, T., Manabe, I., Fukushima, Y. et al. (2002) Kruppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat. Med. 8, 856-863
55. Sakamoto, H., Sakamaki, T., Kanda, T. et al. (2003) Smooth muscle cell outgrowth from coronary atherectomy specimens in vitro is associated with less time to restenosis and expression of a key transcription factor KLF5/BTEB2. Cardiology 100, 80-85
56. Bochaton-Piallat, M. L., Gabbiani, F., Redard, M., Desmouliere, A. and Gabbiani, G. (1995) Apoptosis participates in cellularity regulation during rat aortic intimal thickening. Am. J. Pathol. 146, 1059-1064
57. Han, D. K., Haudenschild, C. C., Hong, M. K., Tinkle, B. T., Leon, M. B. and Liau, G. (1995) Evidence for apoptosis in human atherogenesis and in a rat vascular injury model. Am. J. Pathol. 147, 267-277
58. Fontana, J. A. and Rishi, A. K. (2002) Classical and novel retinoids: their targets in cancer therapy. Leukemia 16, 463-472
59. He, W., Zhao, Y., Song, F., Saitoh, A. and Shimada, S. (2000) Factors influencing the expression of Fas and Fas ligand on newborn murine keratinocytes and fibroblasts. Chin. Med. J. 113, 833-835
60. Ou, H., Haendeler, J., Aebly, M. R. et al. (2000) Retinoic acid-induced tissue transglutaminase and apoptosis in vascular smooth muscle cells. Circ. Res. 87, 881-887
61. Orlandi, A., Francesconi, A., Cocchia, D., Corsini, A. and Spagnoli, L. G. (2001) Phenotypic heterogeneity influences apoptotic susceptibility to retinoic acid and cis-platinum of rat arterial smooth muscle cells in vitro: implications for the evolution of experimental intimal thickening. Arterioscler. Thromb. Vasc. Biol. 21, 1118-1123
62. Futoryan, T. and Gilchrest, B. A. (1994) Retinoids and the skin. Nutr. Rev. 52, 299-310
63. Hong, W. K. and Sporn, M. B. (1997) Recent advances in chemoprevention of cancer. Science 278, 1073-1077
64. Haller, H., Lindschau, C., Quass, P., Distler, A. and Luft, F. C. (1995) Differentiation of vascular smooth muscle cells and the regulation of protein kinase C-α. Circ. Res. 76, 21-29
65. Gollasch, M., Haase, H., Ried, C. et al. (1998) L-type calcium channel expression depends on the differentiated state of vascular smooth muscle cells. FASEB J. 12, 593-601
66. Colbert, M. C., Kirby, M. L. and Robbins, J. (1996) Endogenous retinoic acid signaling colocalizes with advanced expression of the adult smooth muscle myosin heavy chain isoform during development of the ductus arteriosus. Circ. Res. 78, 790-798
67. Wright, G. L., Wang, S., Fultz, M. E., Arif, I., Matthews, K. and Chertow, B. S. (2002) Effect of vitamin A deficiency on cardiovascular function in the rat. Can. J. Physiol. Pharmacol. 80, 1-7
68. Wright, G., Wang, S., Bailey, G., Reichenbecher, V. and Wright, G. L. (1996) Effect of retinoic acid on contractile competence of vascular smooth muscle. Am. J. Physiol. 270, H1363-H1370
69. Fujiu, K., Manabe, I., Ishihara, A. et al. (2005) Synthetic retinoid Am80 suppresses smooth muscle phenotypic modulation and in-stent neointima formation by inhibiting KLF5. Circ. Res. 97, 1132-1141
70. Kooistra, T., Opdenberg, J. P., Toet, K., Hendriks, H. F., van den Hoogen, R. M. and Emeis, J. J. (1991) Stimulation of tissue-type plasminogen activator synthesis by retinoids in cultured human endothelial cells and rat tissues in vivo. Thromb. Haemostasis 65, 565-572
71. Van Bennekum, A. M., Emeis, J. J., Kooistra, T. and Hendriks, H. F. (1993) Modulation of tissue-type plasminogen activator by retinoids in rat plasma and tissues. Am. J. Physiol. 264, R931-R937
72. van Giezen, J. J., Boon, G. I., Jansen, J. W. and Bouma, B. N. (1993) Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis. Thromb. Haemostasis 69, 381-386
73. Back, O. and Nilsson, T. K. (1995) Retinoids and fibrinolysis. Acta Derm. Venereol. 75, 290-292
74. Marchetti, M., Vignoli, A., Bani, M. R., Balducci, D., Barbui, T. and Falanga, A. (2003) All-trans retinoic acid modulates microvascular endothelial cell hemostatic properties. Haematologica 88, 895-905
75. Conese, M., Montemurro, P., Fumarulo, R. et al. (1991) Inhibitory effect of retinoids on the generation of procoagulant activity by blood mononuclear phagocytes. Thromb. Haemostasis 66, 662-665
76. Uruno, A., Sugawara, A., Kudo, M. et al. (2003) Transcription suppression of thromboxane receptor gene expression by retinoids in vascular smooth muscle cells. Hypertens. Res. 26, 815-821
77. Freemantle, S. J., Spinella, M. J. and Dmitrovsky, E. (2003) Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 22, 7305-7315
78. Ozpolat, B., Mehta, K., Tari, A. M. and Lopez-Berestein, C (2002) All-trans-retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukemia. Am. J. Hematol. 70, 39-47
79. Kim, S. Y., Yoo, S. J., Kwon, H. J., Kim, S. H., Byun, Y. and Lee, K. S. (2002) Retinoic acid 4-hydroxylase-mediated catabolism of all-trans retinoic acid and the cell proliferation in head and neck squamous cell carcinoma. Metab. Clin. Exp. 51, 477-481
80. Kagechika, H. and Shudo, K. (2005) Synthetic retinoids: recent developments concerning structure and clinical utility. J. Med. Chem. 48, 5875-5883
81. Njar, V. C., Gediya, L., Purushottamachar, P. et al. (2006) Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Bioorg. Med. Chem. 14, 4323-4340
82. Stoppie, P., Borgers, M., Borghgraef, P. et al. (2000) R115866 inhibits all-trans-retinoic acid metabolism and exerts retinoidal effects in rodents. J. Pharmacol. Exp. Ther. 293, 304-312
83. Kuijpers, A. L., Van Pelt, J. P., Bergers, M. et al. (1998) The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin. Br. J. Dermatol. 139, 380-389
84. Ocaya, P., Gidlöf, A. C., Olofsson, P. S., Torma, H. and Sirsjö, A. (2007) CYP26 inhibitor R115866 increases retinoid signalling in intimal smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 27, 1542-1548
85. Gidlöf, A. C., Ocaya, P., Olofsson, P. S., Torma, H. and Sirsjo, A. (2006) Differences in retinol metabolism and proliferative response between neointimal and medial smooth muscle cells. J. Vasc. Res. 43, 392-398